Table 2.

Comparison of the drug encapsulation properties of epothilone B (EpoB) and rapamycin (Rap) by various PLA-based delivery systems (DDS).

Name of DDS	EE of EpoB (%)	EE of Rap (%)
PLA 100/PLA–PEG 0 + EpoB	8.9 ± 1.2	-
PLA 100/PLA–PEG 0 + Rap	-	83.0 ± 4.2
PLA 100/PLA–PEG 0 + EpoB and Rap	13.1 ± 2.3	48.1 ± 1.5
PLA 75/PLA–PEG 25 + EpoB	7.2 ± 2.3	-
PLA 75/PLA–PEG 25 + Rap	-	96.0 ± 3.7
PLA 75/PLA–PEG 25 + EpoB and Rap	9.4 ± 1.9	54.2 ± 0.9
PLA 50/PLA–PEG 50 + EpoB	2.9 ± 0.2
PLA 50/PLA–PEG 50 + Rap	-	95.0 ± 4.7
PLA 50/PLA–PEG 50 + EpoB and Rap	4.2 ± 1.2	59.7 ± 1.3
PLA 25/PLA–PEG 75 + EpoB	6.8 ± 3.6	-
PLA 25/PLA–PEG 75 + Rap	-	91.0 ± 8.9
PLA 25/PLA–PEG 75 + EpoB and Rap	7.2 ± 2.7	53.9 ± 1.8
Micelles + EpoB	43.8 ± 3.8
Micelles + Rap	-	96.5 ± 3.3
Micelles + EpoB and Rap	41.0 ± 3.8	40.3 ± 0.7